AUTHOR=Tao Xuemei , Xu Changjing , Zhong Xiaoyan , Mou Yao , Li Jingwei , Yang Xuping , Huang Yilan 

TITLE=Real-world Biapenem vs. Meropenem in the treatment of severe community-acquired pneumonia in children: A propensity score matching analysis

JOURNAL=Frontiers in Pediatrics

VOLUME=10

YEAR=2022

URL=https://www.frontiersin.org/journals/pediatrics/articles/10.3389/fped.2022.1047595

DOI=10.3389/fped.2022.1047595

ISSN=2296-2360

ABSTRACT=<sec><title>Objective</title><p>To compare the real-world efficacy and safety of Biapenem and Meropenem for treating severe community-acquired pneumonia (SCAP) in children.</p></sec><sec><title>Methods</title><p>We retrospectively evaluated 915 children with SCAP who were treated with Biapenem or Meropenem from August 2018 to June 2022. A 1:1 propensity score matching (PSM) analysis was used to reduce the actual baseline difference between groups.</p></sec><sec><title>Results</title><p>416 patients participated in the analysis after PSM (Biapenem: Meropenem = 1:1). For the Biapenem group and Meropenem group, the effective rates were 90.4% and 90.9%, respectively (<italic>p </italic>= 1.0) and the incidence of adverse reactions were 7.7% and 7.2%, respectively (<italic>p </italic>= 1.0). There were no statistical differences between Biapenem and Meropenem.</p></sec><sec><title>Conclusion</title><p>In general, the efficacy and safety of Biapenem are comparable to Meropenem in the treatment of children with SCAP.</p></sec>